A phase i trial for evaluating the tolerance of disodium panaxatriol 3,6-succinate

Yan Sun,WANG Hua-qing,Zhao Yan,Zheng Song,ZHANG Hui-lai,LIU Xian-ming,Wei Li
2008-01-01
Abstract:Objective: To evaluate the safety of a new anticancer drug, disodium panaxatriol 3,6-succinate, in human by determining its maximally tolerated dose. Methods: Dose escalation was performed by modified Fibonacci sequence in 30 healthy volunteers and 9 cancer patients. Single doses (20, 40, 70, 100, 140, 190, 240 mg) of disodium panaxatriol 3 ,6-succinate were intravenously infused in 21 healthy volunteers once daily until to MTD. Multiple doses were successively given for 30 d in 9 healthy volunteers (70, 100, 140 mg) and 9 cancer patients (100 mg). Results: No adverse reactions were observed after single doses in 21 healthy volunteers. The major adverse reaction after 30 d multiple doses included hypodynamia, pharyngalgia, dryness-heat and sedes drying in 9 healthy volunteers and 9 cancer patients. Conclusion: The toxicity of disodium panaxatriol 3 ,6-succinate is mild, and subjects can be well tolerated. The recommended dose regimen for phase II trial is 70 ∼ 100 mg·d-1, intravenous infusion, once daily for 30 d.
What problem does this paper attempt to address?